Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
about
Nanodiscs and Solution NMR: preparation, application and challenges.Mapping the Free Energy Landscape of PKA Inhibition and Activation: A Double-Conformational Selection Model for the Tandem cAMP-Binding Domains of PKA RIα.Seeing is believing: Ras dimers observed in live cellsSpecific cancer-associated mutations in the switch III region of Ras increase tumorigenicity by nanocluster augmentation.The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding RegionsFarnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions.Inhibition of prenylated KRAS in a lipid environmentThe disordered hypervariable region and the folded catalytic domain of oncogenic K-Ras4B partner in phospholipid binding.K-Ras at Anionic Membranes: Orientation, Orientation…Orientation. Recent Simulations and Experiments.Oncogenic K-Ras Binds to an Anionic Membrane in Two Distinct Orientations: A Molecular Dynamics Analysis.The higher level of complexity of K-Ras4B activation at the membrane.Regulation of H-Ras-driven MAPK signaling, transformation and tumorigenesis, but not PI3K signaling and tumor progression, by plasma membrane microdomains.Nutrient-Gene Interaction in Colon Cancer, from the Membrane to Cellular Physiology.Inhibition of RAS function through targeting an allosteric regulatory site.Deconstruction of the Ras switching cycle through saturation mutagenesis.Distinct dynamics and interaction patterns in H- and K-Ras oncogenic P-loop mutants.Exploring the interactions of the RAS family in the human protein network and their potential implications in RAS-directed therapies.Nanodiscs for structural and functional studies of membrane proteins.Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.Membrane orientation dynamics of lipid-modified small GTPases.Nanodiscs in Membrane Biochemistry and Biophysics.Recent advances in nanodisc technology for membrane protein studies (2012-2017).Intrinsic protein disorder in oncogenic KRAS signaling.RAS Proteins and Their Regulators in Human Disease.Membrane lipids and cell signaling.Disordered Regions Flanking Ordered Domains Modulate Signaling TransductionMolecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas.Endothelial nitric oxide synthase oxygenase on lipid nanodiscs: A nano-assembly reflecting native-like function of eNOS.Multiple interactions between an Arf/GEF complex and charged lipids determine activation kinetics on the membrane.K-Ras4B Remains Monomeric on Membranes over a Wide Range of Surface Densities and Lipid Compositions.Hierarchical Multicomponent Inorganic Metamaterials: Intrinsically Driven Self-Assembly at the Nanoscale.Spatiotemporal Analysis of K-Ras Plasma Membrane Interactions Reveals Multiple High Order Homo-oligomeric Complexes.Targeting the α4-α5 interface of RAS results in multiple levels of inhibition.KRAS Alleles: The Devil Is in the Detail.Method to Visualize and Analyze Membrane Interacting Proteins by Transmission Electron Microscopy.A "Tug of War" Maintains a Dynamic Protein-Membrane Complex: Molecular Dynamics Simulations of C-Raf RBD-CRD Bound to K-Ras4B at an Anionic Membrane.Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain.Structural Basis of Phosphatidic Acid Sensing by APH in Apicomplexan ParasitesAssessment of mutation probabilities of KRAS G12 missense mutants and their long-timescale dynamics by atomistic molecular simulations and Markov state modeling
P2860
Q30152644-331AF641-EEDF-47F3-AEEE-9BFA3D383755Q35855439-9E560480-D81B-46C3-866C-3F80FAB73A75Q35961154-B5B2763B-6231-40E8-A6A5-CE9C08BB2DE8Q36038664-3086750D-0027-4BEA-8933-CFA7EC27BC43Q36217950-E39C2552-63B2-48B5-906D-57C918C7C2FBQ36237636-F314EB11-CB86-411D-846B-9902855DABE1Q36338169-BA12151B-D9E0-4E98-A866-0FBCB4AC932FQ36669604-40E6CBD6-60EC-4082-BE12-5D0BB36449F1Q36678708-2EAC4B26-259C-4E50-8893-CF9122F57A26Q36678717-4CD7AC9A-7659-4439-8D7D-1855C665A637Q36705290-AE5B52A4-1CCA-40C7-922C-A290417F176CQ37096248-1A05FCE4-8678-4600-814C-635FB997ED60Q37279704-F6839925-C56F-4F84-9570-DBE6525D5397Q37540897-1A4AC38B-D6A2-4D07-936B-A04B6D9282E8Q38689614-DBD62DB4-6842-455B-879E-2536BE294B3EQ38789349-FC5A7925-F7F8-4F18-906A-21306633A639Q38814045-D9749663-1147-4C48-AAFF-24E38980687DQ38858495-D55AFD69-110A-4978-B6B7-C5FBE64B02F1Q38891257-6BCD8E99-2C85-4DE8-BA10-0C16801DC1C7Q38974930-92DBD4D9-DDF5-42FD-85EA-CE0B8D57CE8BQ39126044-D2B5F059-B511-4CF6-8F7A-2E262BB94B9DQ39350771-878ABA63-30C7-4087-9F50-198D27F2E2E0Q39361391-34347FD4-E08B-442D-932C-EB31F9CDFF11Q39407402-4E3A0CE0-90F1-45E9-8A65-1F5534642693Q39425777-5C3F1C26-095B-4FAF-AEDB-367654633750Q41275884-A0CC6D45-9797-4EC2-9E0C-6F1C575B6DFDQ41986841-239AE9DD-B7C7-4840-83EC-0852A3F4E3FFQ46299347-5877CF71-08E2-4544-8CD9-A6B952546DFFQ46328382-FB71B4B6-A81B-47E1-87B3-8912615604E9Q47213711-DA0E9D67-46A2-4474-8F5B-B29C009E4162Q47334520-B972A710-2592-4C95-B6F9-D00B225775C3Q48138939-B03C7C82-2F72-4E91-A8ED-3E40FF0FF6A6Q48151533-0CACC1C6-E361-4DAB-AC4F-E434A9376FE4Q49668169-16094CA3-35D3-42D5-B6EA-7043E95AD5E6Q51100714-704ED3B4-529F-4DBE-8263-7239E981BCEFQ52358078-25C84EE4-2773-45DA-AE8D-51755CD8FD19Q54977434-B33E7413-4DDB-4DA9-BE52-8B046CE637D9Q56559959-AC5089D1-6310-415A-9B4A-7674809D3B87Q58753858-83ADCF62-85A1-4055-A3B7-F8A4A16E04AE
P2860
Oncogenic and RASopathy-associated K-RAS mutations relieve membrane-dependent occlusion of the effector-binding site.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Oncogenic and RASopathy-associ ...... of the effector-binding site.
@ast
Oncogenic and RASopathy-associ ...... of the effector-binding site.
@en
type
label
Oncogenic and RASopathy-associ ...... of the effector-binding site.
@ast
Oncogenic and RASopathy-associ ...... of the effector-binding site.
@en
prefLabel
Oncogenic and RASopathy-associ ...... of the effector-binding site.
@ast
Oncogenic and RASopathy-associ ...... of the effector-binding site.
@en
P2093
P2860
P50
P356
P1476
Oncogenic and RASopathy-associ ...... of the effector-binding site.
@en
P2093
Benjamin G Neel
Geneviève M C Gasmi-Seabrook
Peter B Stathopulos
P2860
P304
P356
10.1073/PNAS.1419895112
P407
P50
P577
2015-05-04T00:00:00Z